Comparative Pharmacology
Head-to-head clinical analysis: DEPODUR versus INFUMORPH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPODUR versus INFUMORPH.
DEPODUR vs INFUMORPH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Morphine sulfate extended-release liposomal injection; morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The analgesic effects are mediated by activation of mu-opioid receptors in the central nervous system, leading to modulation of pain pathways.
Morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. It mimics endogenous endorphins by binding to opioid receptors in the CNS, causing inhibition of ascending pain pathways and altering pain perception.
Epidural: 5-15 mg as a single dose (morphine sulfate 10 mg/mL extended-release liposome injection).
Morphine sulfate 10-30 mg orally every 4 hours as needed; or 2.5-15 mg IV/IM/SC every 2-6 hours; or 0.5-2 mg per hour continuous IV infusion. Extended-release formulations: 15-30 mg orally every 8-12 hours.
None Documented
None Documented
The terminal elimination half-life of morphine is approximately 2-4 hours in adults. However, DEPODUR (extended-release liposomal morphine) has a prolonged half-life due to slow release from the liposomal depot, with an effective half-life of about 12-24 hours, supporting once-daily dosing.
Terminal elimination half-life: 2–4 hours in healthy adults; prolonged to 4–6 hours in the elderly or those with renal impairment, leading to accumulation of active metabolites (M6G).
Morphine is primarily excreted renally, with approximately 90% of the dose eliminated in urine within 24 hours, mainly as morphine-3-glucuronide (M3G, ~50%), morphine-6-glucuronide (M6G, ~10%), and unchanged morphine (~10%). Fecal excretion accounts for less than 10%.
Renal elimination of morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) accounts for approximately 90% of total clearance, with <10% excreted as unchanged morphine in urine. Biliary/fecal elimination accounts for the remaining fraction (<10%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic